HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sana D Karam Selected Research

EphB4 Receptor

1/2022EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment.
1/2020The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme.
12/2016Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sana D Karam Research Topics

Disease

62Neoplasms (Cancer)
11/2022 - 01/2012
23Squamous Cell Carcinoma of Head and Neck
05/2022 - 01/2014
15Head and Neck Neoplasms (Head and Neck Cancer)
11/2021 - 01/2014
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2022 - 01/2013
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2022 - 01/2017
4Medulloblastoma
01/2017 - 04/2015
3Neoplasm Metastasis (Metastasis)
01/2021 - 01/2014
3Oropharyngeal Neoplasms
01/2019 - 11/2018
3Carcinoma (Carcinomatosis)
11/2018 - 06/2012
3Laryngeal Neoplasms (Laryngeal Cancer)
02/2017 - 01/2017
2Adenocarcinoma
01/2022 - 04/2021
2Pancreatic Neoplasms (Pancreatic Cancer)
04/2021 - 01/2021
2Fibrosis (Cirrhosis)
01/2021 - 01/2019
2Melanoma (Melanoma, Malignant)
10/2018 - 12/2017
2Brain Neoplasms (Brain Tumor)
10/2018 - 12/2017
1Mouth Neoplasms (Oral Cancer)
01/2022
1Stomatitis
01/2022
1Epstein-Barr Virus Infections
12/2021
1Neoplasm Micrometastasis
11/2021
1Ependymoma
12/2019
1Hyperlipidemias (Hyperlipidemia)
01/2019
1Squamous Cell Neoplasms (Squamous Cell Cancer)
01/2019
1Dehydration (Water Stress)
11/2018
1Vomiting
11/2018
1Nausea
11/2018
1Pneumonia (Pneumonitis)
11/2018
1Diarrhea
11/2018
1Dermatitis
10/2018
1Anaplastic Thyroid Carcinoma
01/2018

Drug/Important Bio-Agent (IBA)

7Proteins (Proteins, Gene)FDA Link
05/2022 - 04/2015
5Immune Checkpoint InhibitorsIBA
01/2021 - 01/2017
5Cetuximab (Erbitux)FDA Link
01/2021 - 09/2017
4Biomarkers (Surrogate Marker)IBA
11/2022 - 01/2020
4Messenger RNA (mRNA)IBA
01/2018 - 04/2015
3EphB4 ReceptorIBA
01/2022 - 12/2016
3Cisplatin (Platino)FDA LinkGeneric
01/2019 - 09/2017
3LigandsIBA
01/2017 - 04/2015
3Phosphotransferases (Kinase)IBA
12/2016 - 04/2015
3tyrosine receptor (receptor, tyrosine)IBA
12/2016 - 04/2015
2InterferonsIBA
05/2022 - 01/2021
2Antisense OligonucleotidesIBA
03/2022 - 04/2021
2Biological ProductsIBA
01/2022 - 01/2021
2Neoplasm Antigens (Tumor Antigens)IBA
01/2022 - 12/2019
2Pharmaceutical PreparationsIBA
01/2022 - 01/2021
2CytokinesIBA
01/2022 - 11/2021
2ChemokinesIBA
04/2021 - 01/2020
2olaparibIBA
01/2020 - 10/2018
2Proliferating Cell Nuclear Antigen (PCNA)IBA
01/2020 - 09/2015
2Ephrin-B2 (Ephrin B2)IBA
01/2018 - 01/2017
2EphrinsIBA
09/2015 - 04/2015
1IntegrinsIBA
05/2022
1Laminin (Merosin)IBA
05/2022
1CarcinogensIBA
01/2022
1tat Gene Products (tat Protein)IBA
01/2022
1Therapeutic UsesIBA
01/2022
1Ephrin-B1 (Ephrin B1)IBA
11/2021
1flt3 ligand protein (flt3 ligand)IBA
11/2021
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
11/2021
1Angiotensin Receptor AntagonistsIBA
11/2021
1Membrane Proteins (Integral Membrane Proteins)IBA
01/2021
1Metalloproteases (Metalloproteinases)IBA
01/2021
1liquid crystal polymerIBA
01/2021
1Gefitinib (Iressa)FDA Link
01/2021
1ErbB Receptors (EGF Receptor)IBA
01/2021
1Anaphylatoxin C5a ReceptorIBA
01/2021
1Complement C3a (Complement 3a)IBA
01/2021
1B7-H1 AntigenIBA
01/2021
1DisintegrinsIBA
01/2021
1AZD 8931IBA
01/2021
1Transforming Growth Factor beta (TGF-beta)IBA
01/2021
1Complement System Proteins (Complement)IBA
01/2021
1Cadherins (E-Cadherin)IBA
01/2020
1VimentinIBA
01/2020
1Fluorouracil (Carac)FDA LinkGeneric
12/2019
1LipidsIBA
01/2019
1atezolizumabIBA
01/2019
1Collagenases (Collagenase)FDA Link
01/2019
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2019
1Opioid Analgesics (Opioids)IBA
01/2019
1AntiemeticsIBA
11/2018
1Carboplatin (JM8)FDA LinkGeneric
11/2018
1Poly(ADP-ribose) Polymerase InhibitorsIBA
10/2018
1Antineoplastic Agents (Antineoplastics)IBA
01/2018
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2018
1Small Interfering RNA (siRNA)IBA
01/2018

Therapy/Procedure

39Radiotherapy
06/2022 - 01/2012
25Therapeutics
11/2022 - 01/2014
11Immunotherapy
05/2022 - 01/2017
8Drug Therapy (Chemotherapy)
01/2019 - 01/2014
4Chemoradiotherapy
01/2022 - 01/2016
4Aftercare (After-Treatment)
01/2019 - 01/2014
3Neoadjuvant Therapy
01/2022 - 08/2017
3Re-Irradiation
01/2021 - 06/2012
2Radioimmunotherapy
11/2021 - 01/2019
2Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
10/2018 - 01/2014
2Induction Chemotherapy
02/2017 - 01/2017
2Combined Modality Therapy
01/2016 - 01/2014
1Pancreatectomy
01/2022
1Esophagectomy
08/2019
1Pain Management
01/2019